BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: prostate cancer
Age: Between 18 - 100 Years
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Males 18 years or older
- Diagnosis of Prostate Adenocarcinoma
For a full list of participation criteria, please visit clinicaltrials.gov.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required